Tetracycline hydrochloride - Generic Drug Details

What are the generic sources for tetracycline hydrochloride and what is the scope of patent protection?

Tetracycline hydrochloride is the generic ingredient in fourteen branded drugs marketed by Avet, Bristol, Warner Chilcott, Pharmacia And Upjohn, Solvay, Wyeth Ayerst, Apothecon, Angus, Abbott, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma Usa, Breckenridge, Chartwell Tetra, Elkins Sinn, Ferrante, Heather, Hikma, Impax Labs, Ivax Sub Teva Pharms, Mast Mm, Novitium Pharma, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Superpharm, Valeant Pharm Intl, Watson Labs, Pfipharmecs, Schiff And Co, Shire, Lederle, Pfizer, Storz, Ph Health, Alpharma Us Pharms, Proter, and Strides Pharma Intl, and is included in fifty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are forty-nine drug master file entries for tetracycline hydrochloride. Eight suppliers are listed for this compound.

Summary for tetracycline hydrochloride

US Patents:	0
Tradenames:	14
Applicants:	39
NDAs:	53
Drug Master File Entries:	49
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	253
Patent Applications:	6,359
What excipients (inactive ingredients) are in tetracycline hydrochloride?	tetracycline hydrochloride excipients list
DailyMed Link:	tetracycline hydrochloride at DailyMed

Recent Clinical Trials for tetracycline hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
The First Affiliated Hospital with Nanjing Medical University	PHASE4
Kaohsiung Veterans General Hospital.	NA

See all tetracycline hydrochloride clinical trials

Pharmacology for tetracycline hydrochloride

Drug Class

Tetracycline-class Antimicrobial

Anatomical Therapeutic Chemical (ATC) Classes for tetracycline hydrochloride

A01AB	Antiinfectives and antiseptics for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

D06AA	Tetracycline and derivatives
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J01AA	Tetracyclines
J01A	TETRACYCLINES
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for tetracycline hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Sub Teva Pharms	TETRACYCLINE HYDROCHLORIDE	tetracycline hydrochloride	CAPSULE;ORAL	060704-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Angus	TETRACHEL	tetracycline hydrochloride	CAPSULE;ORAL	060343-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	TETRACYCLINE HYDROCHLORIDE	tetracycline hydrochloride	CAPSULE;ORAL	060471-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Novitium Pharma	TETRACYCLINE HYDROCHLORIDE	tetracycline hydrochloride	CAPSULE;ORAL	212635-002	Mar 3, 2020	AB	RX	No	No

Market Dynamics and Financial Trajectory for Tetracycline Hydrochloride

Last updated: February 13, 2026

Overview

Tetracycline hydrochloride is an established antibiotic used to treat a broad range of bacterial infections. It was first introduced in the 1940s and remains in use today, primarily in developing regions. Its production and market are influenced by drug resistance issues, regulatory status, manufacturing costs, and competition from newer antibiotics.

Market Size and Segmentation

The global tetracycline market is modest compared to broader antibiotics, owing to its age, resistance concerns, and regulatory restrictions in some markets. In 2022, the global antibiotics market was valued at approximately $50 billion, with tetracyclines accounting for an estimated $2-3 billion. Tetracycline hydrochloride sales represent around 40% of tetracycline antibiotic revenue, roughly $800 million to $1.2 billion.

Geographical segmentation indicates higher consumption in Asia-Pacific, which accounts for approximately 55% of sales due to manufacturing, pricing, and endemic bacterial infections. North America and Europe hold the remaining 45%, with usage declining owing to resistance and newer treatment protocols.

Production and Supply Chain

The majority of tetracycline hydrochloride is produced in China and India, with several active pharmaceutical ingredient (API) manufacturers operating at scale. With the shift of API manufacturing to low-cost regions, the supply chain is globally integrated but vulnerable to regulatory scrutiny, trade disruptions, and environmental concerns related to manufacturing residues.

Market Drivers

1. Cost-Effectiveness: Tetracycline remains inexpensive, with retail prices significantly lower than newer antibiotics, maintaining its role in low-income countries.

2. Established Usage: Its broad-spectrum activity and familiarity among healthcare providers sustain demand for certain infections.

3. Regulatory Status: Approvals in many countries are stable, but some jurisdictions have strict controls due to resistance issues.

Market Restraints

1. Antibiotic Resistance: Resistance rates for tetracyclines including tetracycline hydrochloride have risen globally. In some regions, resistance exceeds 50% for common pathogens, limiting clinical efficacy and prescription.

2. Regulatory Restrictions: Increasing restrictions on antibiotics, especially in high-income markets, diminish approval prospects for new formulations or higher doses.

3. Environmental Concerns: Manufacturing residues contribute to environmental antimicrobial resistance proliferation, leading to tighter regulation.

Competitive Landscape

Tetracycline faces competition chiefly from newer antibiotics with better safety, efficacy, and resistance profiles, such as doxycycline and tigecycline. Innovations have been limited, with few new tetracycline formulations or derivatives entering the market recently.

Financial Trajectory and Revenue Outlook

Forecasting over the next five years indicates a gradual decline in tetracycline hydrochloride revenues due to resistance and regulatory pressures. Revenue estimates project a compound annual decline rate (CAGR) of approximately 3-5%, driven by declining demand in developed markets and steady consumption in emerging economies.

While the total global market for tetracycline hydrochloride remains around $1 billion, regional differences cause variability. India and China will sustain production and export volumes due to domestic demand and manufacturing capacity, but global sales in high-income countries will likely continue decreasing.

Pricing Trends

Pricing is expected to decline marginally, influenced by generic competition and regulatory costs. In low-income regions, price stabilization is possible amid sustained demand, but in high-income areas, cost reductions will be driven by manufacturer efficiencies.

Regulatory Forecasts

European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and other health authorities have issued or are considering restrictions on tetracycline antibiotics owing to resistance concerns. Ongoing monitoring and potential Phase-out of certain uses are anticipated, further impacting market size.

Key Data Summary

Aspect	Details
2022 Market Size	~$800 million - $1.2 billion
Leading Regions	Asia-Pacific (55%), North America & Europe (45%)
CAGR Forecast (2023-2028)	-3% to -5%
Primary Competitors	Doxycycline, Tigecycline
Resistance Rates (Global)	30%–50% in various bacterial strains
Manufacturing Countries	China, India

Conclusion

Tetracycline hydrochloride's global market shows signs of maturity and decline, driven by resistance and regulation but persists due to cost advantages and longstanding clinical use. Companies assessing growth opportunities should consider emerging markets and formulations targeting resistant strains or combination therapies as potential avenues.

---

Key Takeaways

• Tetracycline hydrochloride's market is approximately $1 billion globally, with regional variances.
• Resistance limits prescription, especially in high-income countries; emerging markets sustain demand.
• Global revenues decline at 3-5% annually, driven by regulatory restrictions and newer antibiotics.
• Supply chain concentration in China and India exposes vulnerability to geopolitical and environmental regulations.
• Investment or R&D efforts should target resistance management or alternative formulations, given the shrinking market.

---

FAQs

1. What factors are primarily driving the decline in tetracycline hydrochloride sales?
Rising bacterial resistance, regulatory restrictions, and competition from newer antibiotics contribute to reduced demand, especially in developed markets.

2. How does regional variation affect the market prospects for tetracycline hydrochloride?
Developing countries maintain higher consumption due to lower prices and endemic infections, whereas markets in North America and Europe see declining use.

3. Is there any ongoing innovation in tetracycline formulations?
Limited new development is occurring; most efforts focus on alternative antibiotics or resistance mitigation strategies rather than novel tetracycline derivatives.

4. What risks threaten the supply chain of tetracycline hydrochloride?
Regulatory crackdowns on manufacturing residues, trade restrictions, and environmental policies pose risks, primarily centered in China and India.

5. Are there any regulatory changes expected that could impact the market?
Yes, authorities in Europe and North America are considering stricter antibiotic use regulations due to resistance concerns, potentially reducing approved indications for tetracycline hydrochloride.